Harpreet Singh on Clinical Trial Eligibility in the Elderly Cancer Population

Video

Harpreet Singh of the FDA discusses how clinical trial populations are not always reflective of the population of patients who eventually end up getting treated by the therapies.

Harpreet Singh of the FDA discusses how clinical trial populations are not always reflective of the population of patients who eventually end up getting treated by the therapies.

Clinical trials typically enroll patients who are under 65 years of age, though many patients with cancer are older. The FDA formed a group to look into the reasons for this discrepancy and found that strict eligibility criteria, for example, not allowing anyone with organ dysfunction to enroll, is a frequent reason that older patients are deemed ineligible for a trial.

Singh asks if these criteria are always necessary, especially when testing immunotherapies, which tend to have fewer toxicities and side effects.

Recent Videos
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
5 experts in this video
5 experts in this video
Screen capture of Seth Eisenberg, ASN, RN, OCN, BMTCN, on a video call with an Oncology Nursing News branded border around the frame
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
Related Content